Bilateral mastectomy and breast-conserving surgery have equal impact on breast cancer-specific mortality in pathogenic BRCA1 carriers Presented ByDr Kelly Metcalfe, Women’s College Research Institute Toronto, Canada ConferenceSABCS 2023 11 January, 2024 15:03
Highest benefit of neoadjuvant nivolumab in breast tumours with high PD-L1 expression and/or low ER expression Presented ByDr Sherene Loi, Peter MacCallum Cancer Centre, Australia TrialPhase 3, CheckMate 7FL ConferenceSABCS 2023 11 January, 2024 15:02
(More) axillary surgery does not influence long-term recurrence Presented ByDr Gurdeep Mannu, University of Oxford, UK ConferenceSABCS 2023 11 January, 2024 15:01
Neoadjuvant chemotherapy may help patients skip regional nodal irradiation Presented ByProf. Eleftherios Mamounas, Orlando Health Cancer Institute, FL, USA TrialPhase 3, NSABP B-51/RTOG 1304 ConferenceSABCS 2023 11 January, 2024 15:01
No radiotherapy after breast-conserving surgery is safe in selected younger patients Presented ByDr Reshma Jagsi, Emory University School of Medicine, MI, USA TrialIDEA ConferenceSABCS 2023 11 January, 2024 15:01
Tucatinib improves PFS in metastatic, HER2-positive breast cancer Presented ByProf. Sara Hurvitz, Fred Hutchinson Cancer Center, WA, USA TrialPhase 3, HER2CLIMB-02 ConferenceSABCS 2023 11 January, 2024 15:01
OS benefit of adjuvant T-DM1 in early breast cancer with residual disease after neoadjuvant therapy Presented ByProf. Sibylle Loibl, Goethe University, Germany TrialPhase 3, KATHERINE ConferenceSABCS 2023 11 January, 2024 15:01
Atezolizumab improves pCR in HER2-positive early breast cancer Presented ByDr Luca Gianni, IRCCS Ospedale San Raffaele, Italy TrialPhase 3, APTneo ConferenceSABCS 2023 11 January, 2024 15:00
Adjuvant ribociclib improves IDFS in early breast cancer Presented ByDr Gabriel Hortobagyi, MD Anderson Cancer Center, TX, USA TrialPhase 3, NATALEE ConferenceSABCS 2023 11 January, 2024 14:59
Addition of inavolisib to palbociclib and fulvestrant reduces risk of progression Presented ByProf. Komal Jhaveri, Memorial Sloan Kettering Cancer Center, NY, USA TrialPhase 3, INAVO120 ConferenceSABCS 2023 11 January, 2024 14:59
Endocrine therapy response provides information on need of adjuvant chemotherapy Presented ByProf. Oleg Gluz, Breast Center Niederrhein, Germany TrialPhase 3, ADAPTcycle ConferenceSABCS 2023 11 January, 2024 14:58
monarchE: No predictive biomarkers revealed with molecular profiling Presented ByProf. Nick Turner, The Royal Marsden Hospital and Institute of Cancer Research, UK TrialPhase 3, monarchE ConferenceSABCS 2023 11 January, 2024 14:58
No predictive biomarkers found in PALLAS Presented ByDr Daniel Stover, The Ohio State University, OH, USA TrialPhase 3, PALLAS ConferenceSABCS 2023 11 January, 2024 14:57
Olaparib maintenance has favourable safety profile in TNBC Presented ByProf. Hope Rugo, UCSF Helen Diller Family Comprehensive Cancer Center, CA, USA TrialPhase 2, KEYLYNK-009 ConferenceSABCS 2023 11 January, 2024 14:57
High pCR with neoadjuvant nivolumab/chemotherapy in stage I–II TNBC Presented ByDr Nicholas Zdenkowski, University of Newcastle, Australia TrialPhase 2, Neo-N ConferenceSABCS 2023 11 January, 2024 14:57
Exercise programme improves quality of life for patients with metastatic breast cancer Presented ByProf. Anne May, University Medical Center Utrecht, the Netherlands TrialPREFERABLE-EFFECT ConferenceSABCS 2023 11 January, 2024 14:57
Fast menstrual resumption after interruption of endocrine therapy Presented ByDr Hatem Azim, Monterrey Institute of Technology, Mexico TrialPOSITIVE ConferenceSABCS 2023 11 January, 2024 14:55
Pregnancy is not contraindicated in pathogenic BRCA carriers Presented ByDr Matteo Lambertini, University of Genova, Italy ConferenceSABCS 2023 11 January, 2024 14:55
Benefit of pembrolizumab in TNBC remains after 5 years of follow-up Presented ByProf. Peter Schmid, Barts Cancer Institute, UK TrialPhase 3, KEYNOTE-522 ConferenceESMO 2023 18 December, 2023 15:50
Addition of pembrolizumab promising in early-stage high-risk ER+/HER2- breast cancer Presented ByDr Fatima Cardoso, Champalimaud Clinical Centre, Portugal TrialPhase 3, KEYNOTE-756 trial ConferenceESMO 2023 18 December, 2023 15:48
Long-term air pollution exposure at both residential and workplace locations increases breast cancer risk Presented ByProf. Béatrice Fervers, Centre Léon Bérard, France ConferenceESMO 2023 18 December, 2023 15:45
Third-line datopotamab deruxtecan improves progression-free survival in previously treated metastatic HR+/HER2- breast cancer compared with chemotherapy Presented ByDr Aditya Bardia, Massachusetts General Hospital, USA TrialPhase 3, TROPION-Breast01 ConferenceESMO 2023 18 December, 2023 15:41
Know Your Lemons for breast cancer detection ExpertDr Corrine Ellsworth-Beaumont, Know Your Lemons Foundation, Salt Lake City, Utah, USA 26 October, 2023 20:13
A systematic review of interventions to improve AET adherence in breast cancer survivors TrialReview study 24 October, 2023 17:31
SONIA: No survival benefit with first-line versus second-line CDK4/6 inhibition in metastatic breast cancer Presented ByProf. Gabe Sonke, Netherlands Cancer Institute, the Netherlands TrialPhase 3, SONIA ConferenceASCO 2023 2 August, 2023 09:55
Adjuvant ribociclib improves invasive DFS in early breast cancer Presented ByProf. Dennis Slamon, David Geffen School of Medicine, CA, USA TrialPhase 3, NATALEE ConferenceASCO 2023 2 August, 2023 09:52
Gene expression profiles predict benefit of neoadjuvant immune checkpoint therapy in triple-negative breast cancer Presented ByDr Hanna Huebner, Erlangen University Hospital, Germany TrialPhase 2, GeparNuevo ConferenceASCO 2023 2 August, 2023 09:49
ASCO 2023 Highlights Podcast Presented ByDr Rachel Giles, Medicom ConferenceASCO 2023 26 June, 2023 03:07
Racial disparity in the tumour microenvironment Presented ByDr Burcu Karadal-Ferrena, Albert Einstein College of Medicine, NY, USA ConferenceSABCS 2022 1 February, 2023 18:42
Chemo-endocrine therapy worse for cognition than endocrine therapy alone Presented ByDr Irene Kang, City of Hope Orange County, CA, United States TrialRxPONDER PRO ConferenceSABCS 2022 1 February, 2023 18:36
Resistance to CDK4/6 inhibitors is likely due to expansion of pre-existing resistant clones Presented ByDr Cristina Guarducci, Dana-Farber Cancer Institute, MA, USA ConferenceSABCS 2022 1 February, 2023 18:32
Baseline CTC count can guide first-line treatment in HR-positive/HER-negative metastatic breast cancer Presented ByProf. François-Clément Bidard, Institut Curie, France TrialPhase 3, STIC CTC ConferenceSABCS 2022 1 February, 2023 18:30
Germline pathogenic variants for breast cancer also increase contralateral breast cancer risk Presented ByProf. Siddhartha Yadav, Mayo Clinic, MN, USA TrialCARRIERS ConferenceSABCS 2022 1 February, 2023 18:27
Low-dose tamoxifen still prevents recurrence from non-invasive breast cancer Presented ByDr Andrea De Censi, Ospedali Galliera, Italy TrialPhase 3, TAM-01 ConferenceSABCS 2022 1 February, 2023 18:24
Endocrine interruption to pursue pregnancy does not impact short-term disease in breast cancer Presented ByDr Ann Partridge, Dana-Farber Cancer Institute, MA, USA TrialPOSITIVE ConferenceSABCS 2022 1 February, 2023 18:22
ZNF689 deficiency promotes intratumour heterogeneity and resistance to immune checkpoint blockade in TNBC Presented ByDr Li-Peng Ge, Fudan University Shanghai Cancer Center, China ConferenceSABCS 2022 1 February, 2023 18:17
Oestradiol represses anti-tumoural immune response to promote progression of brain metastases Presented ByDr Maria Contreras-Zarate, University of Colorado, CO, USA ConferenceSABCS 2022 1 February, 2023 18:14
Benefit of adjuvant abemaciclib continues to deepen at longer follow-up Presented ByProf. Stephen Johnston, The Royal Marsden NHS Foundation Trust, UK TrialPhase 3, monarchE ConferenceSABCS 2022 1 February, 2023 18:10
First-line ribociclib plus endocrine therapy outperforms combination chemotherapy Presented ByDr Yen-Shen Lu, National Taiwan University Hospital, Taiwan TrialPhase 2, RIGHT Choice ConferenceSABCS 2022 1 February, 2023 18:07
Treatment options beyond CDK4/6 inhibition Presented ByDr Erica Mayer (Dana-Farber Cancer Institute, MA, USA); Prof. Virginia Kaklamani (University of Texas Health Sciences Center, TX, USA); TrialPACE; EMERALD; SERENA-2; CAPItello-291; VERITAC ConferenceSABCS 2022 1 February, 2023 18:03
Trastuzumab deruxtecan effective in both second-line and neoadjuvant setting Presented ByDr Ian Krop (Yale Cancer Center, CT, USA); Prof. Sara Hurvitz (David Geffen School of Medicine, CA, USA); Prof. Aditya Bardia (Harvard Medical School, MA, USA) TrialPhase 3, DESTINY-Breast02; DESTINY-Breast03; TRIO-US B-12 TALENT ConferenceSABCS 2022 1 February, 2023 17:51
Anti-PD-1/anti-LAG-3 combination highly effective in HER2-negative breast cancer Presented ByProf. Claudine Isaacs, Georgetown University Medical Center, DC, USA TrialPhase 2, I-SPY 2 ConferenceSABCS 2022 1 February, 2023 17:42
MammaPrint test predictive for benefit of extended endocrine therapy Presented ByDr Laura van ‘t Veer, UCLA, CA, USA TrialPhase 3, IDEAL ConferenceSABCS 2022 1 February, 2023 17:32
Tumour infiltrating lymphocytes identify patients with immunogenic triple-negative breast cancer Presented ByProf. Marleen Kok, Netherlands Cancer Institute, the Netherlands) TrialPhase 2, BELLINI ConferenceESMO 2022 16 November, 2022 18:01
OS benefit of abemaciclib in HR-positive/HER2-negative advanced breast cancer not (yet) statistically significant Presented ByProf. Matthew Goetz, Mayo Clinic Rochester, MN, USA TrialPhase 3, MONARCH 3 ConferenceESMO 2022 16 November, 2022 17:48
OS benefit of sacituzumab govitecan in pre-treated HR-positive/HER2-negative metastatic breast cancer Presented ByProf. Hope Rugo, Helen Diller Family Comprehensive Cancer Centre, CA, USA TrialPhase 3, TROPiCS-02 ConferenceESMO 2022 16 November, 2022 17:43
Bacterial decolonisation effective against radiation dermatitis Presented ByMs Yana Kost, Albert Einstein College of Medicine, NY, USA ConferenceASCO 2022 5 August, 2022 15:38
Sacituzumab govitecan meets primary endpoint Presented ByProf. Hope Rugo, University of California San Francisco, CA, USA TrialPhase 3, TROPiCS-02 ConferenceASCO 2022 5 August, 2022 12:11
Shaky OS results of palbociclib in ER-positive/HER2-negative breast cancer Presented ByProf. Richard Finn, David Geffen School of Medicine at UCLA, CA, USA TrialPhase 3, PALOMA-2 ConferenceASCO 2022 5 August, 2022 12:09
Practice-changing results of T-DXd in HER2-low breast cancer Presented ByProf. Shanu Modi, Memorial Sloan Kettering Cancer Center, NY, USA TrialPhase 3, DESTINY-Breast04 ConferenceASCO 2022 5 August, 2022 12:04
SET2,3 to inform on chemotherapy decisions in ER-positive breast cancer Presented ByDr Otto Metzger, Dana-Farber Cancer Institute, MA, USA TrialPhase 3, CALGB9741 ConferenceASCO 2022 5 August, 2022 11:59
Metastasis-directed therapy fails in oligometastatic breast cancer Presented ByDr Steven Chmura, University of Chicago, IL, USA TrialPhase 2, NRG-BR002 ConferenceASCO 2022 5 August, 2022 11:34
Analysis by residual cancer burden further clarifies effect of pembrolizumab Presented ByProf. Lajos Pusztai, Yale School of Medicine, CT, USA TrialPhase 3, KEYNOTE-522 ConferenceASCO 2022 5 August, 2022 11:26
Contribution of metastatic therapies on mortality reduction in breast cancer Presented ByProf. Jennifer Caswell-Jin, Stanford University, CA, USA ConferenceASCO 2022 5 August, 2022 11:19
Radiotherapy may be omitted in breast cancer patients Presented ByProf. Timothy Whelan, McMaster University, Canada TrialLUMINA ConferenceASCO 2022 5 August, 2022 10:59
Promising data for ribociclib after progression on ET plus CDK4/6 inhibitors in HR-positive/HER2-negative metastatic breast cancer Presented ByProf. Kevin Kalinsky, Winship Cancer Institute of Emory University, GA, USA TrialPhase 2, MAINTAIN ConferenceASCO 2022 5 August, 2022 10:53
7-gene biosignature: Benefits of endocrine therapy and radiotherapy in breast cancer risk groups Presented ByDr Pat Whitworth, Nashville Breast Cancer Center, TN, USA ConferenceASCO 2022 5 August, 2022 10:44
ASCO 2022 Highlights Podcast Presented ByDr Robert van den Heuvel, Medicom ConferenceASCO 2022 21 June, 2022 09:38
Diagnostic mammogram accuracy varies across racial/ethnic groups JournalCancer Epidemiology, Biomarkers & Prevention 20 June, 2022 15:39
Radiation skin toxicity in women with larger breasts is reduced with prone positioning JournalJAMA Oncology 13 June, 2022 14:02
Promising reversal in early-stage breast cancer surgical choices JournalJAMA Surgery 9 June, 2022 18:16
Gilead drug modestly delays breast cancer progression in late-stage trial ConferenceASCO 2022 6 June, 2022 16:10
New data sets stage for broader use of AstraZeneca breast cancer drug ConferenceASCO 2022 6 June, 2022 16:00
Lumpectomy on par with mastectomy for some young women ConferenceAmerican Society of Breast Surgeons annual meeting 13 April, 2022 16:05
Positive lymph nodes not a reliable indicator for chemo in some women with breast cancer ConferenceAmerican Society of Breast Surgeons annual meeting 12 April, 2022 18:14
Trastuzumab deruxtecan slashes disease progression, death by 72% in HER-2+ breast cancer JournalThe New England Journal of Medicine 23 March, 2022 23:00
Mammograms may provide clues to heart-disease risk in older women JournalCirculation: Cardiovascular Imaging 15 March, 2022 19:33
Breast, cervical screening suboptimal in transgender individuals JournalAmerican Journal of Clinical Oncology 10 March, 2022 23:32
Trispecific antibody activates CD 4 cells to curb breast cancer growth in mice JournalNature 10 March, 2022 01:16
Adding ribociclib to letrozole boosts survival in some with advanced breast cancer JournalThe New England Journal of Medicine 9 March, 2022 23:00
One in seven breast cancers “overdiagnosed” in women 50-74 JournalAnnals of Internal Medicine 28 February, 2022 23:23
Breast cancer therapy-related cardiac dysfunction likely diagnosed more accurately with combined testing JournalJAMA Cardiology 17 February, 2022 22:49
Early MRI breast-cancer screening could benefit women with non-BRCA mutations JournalJAMA Oncology 17 February, 2022 17:49
SABCS 2021 Focus in Genomic Profiling Presented ByDr Rachel Giles, Medicom ConferenceSABCS 2021 17 February, 2022 11:10
Use of sentinel-lymph-node biopsies rising in patients with inflammatory breast cancer, against guidelines JournalJAMA Network Open 15 February, 2022 17:50
DNA damage repair may be key to higher breast cancer mortality in Black women JournalTherapeutic Advances in Medical Oncology 14 February, 2022 23:23
Pyrotinib plus capecitabine promising for HER2-positive breast cancer brain metastases JournalThe Lancet Oncology 11 February, 2022 22:43
Use of trastuzumab deruxtecan in breast cancer trials likely guided by inaccurate assays JournalJAMA Oncology 9 February, 2022 23:31
Pembrolizumab logs 37% improvement in event-free survival in triple-negative breast cancer JournalThe New England Journal of Medicine 9 February, 2022 23:00
CECR2 protein pinpointed as driver of breast cancer metastases JournalScience Translational Medicine 8 February, 2022 22:20
Breast cancer subtypes vary by gene, affecting risk prediction, screening strategies JournalJAMA Oncology 2 February, 2022 23:03
Olaparib is well tolerated as an additional treatment Presented ByDr Patricia Ganz, UCLA School of Medicine, CA, USA TrialPhase 3, OlympiA ConferenceSABCS 2021 31 January, 2022 22:26
Race effects the likelihood to develop lymphoedema following breast cancer treatment Presented ByDr Andrea Barrio, Memorial Sloan-Kettering Cancer Center, NY, USA TrialPhase 2, I-SPY ConferenceSABCS 2021 31 January, 2022 22:25
Sentinel lymph node staging is non-inferior to complete axillary lymph node dissection Presented ByDr Damiano Gentile, Humanitas Research Hospital, Italy TrialSINODAR ONE ConferenceSABCS 2021 31 January, 2022 22:23
One in 7 breast cancers detected during screening are overdiagnosed Presented ByDr Marc Ryers , Duke University Medical Center, NC, USA ConferenceSABCS 2021 31 January, 2022 22:21
Using genomics to match treatments improves outcomes Presented ByProf. Fabrice André, Institut Gustave Roussy, France TrialPhase 2, SAFIR02-BREAST; SAFIR-PI3K ConferenceSABCS 2021 31 January, 2022 22:19
How tamoxifen can induce uterine cancer Presented ByDr Kirsten Kübler, Broad Institute, MA, USA ConferenceSABCS 2021 31 January, 2022 22:15
Loss of ASXL1 tumour suppressor promotes resistance to CDK4/6 inhibitors Presented ByDr Dhivya Sudhan, UT Southwestern Medical Center, TX, USA ConferenceSABCS 2021 31 January, 2022 22:12
Inducers of ferroptosis are potential drugs to target p53-mutated TNBC cells Presented ByDr William Tahaney, MD Anderson Cancer Center, TX, USA ConferenceSABCS 2021 31 January, 2022 22:10
MAPK-pathway alterations are associated with resistance to anti-HER2 therapy Presented ByDr Emanuela Ferraro, Memorial Sloan-Kettering Cancer Center, NY, USA ConferenceSABCS 2021 31 January, 2022 22:08
Genomic signatures of DCIS define biology and correlate with clinical outcomes Presented ByDr Siri Strand, Stanford University, CA, USA TrialTBCRC 038;RAHBT ConferenceSABCS 2021 31 January, 2022 18:11
BRCA2 linked to inferior outcomes with CDK4/6 inhibitors plus endocrine therapy Presented ByDr Anton Safonov, Memorial Sloan-Kettering Cancer Center, NY, USA ConferenceSABCS 2021 31 January, 2022 18:08
Datopotamab deruxtecan shows promising anti-tumour activity Presented ByDr Ian Krop, Dana-Farber Cancer Institute, MA, USA TrialPhase 1, TROPION-PanTumor01 ConferenceSABCS 2021 31 January, 2022 18:05
Trastuzumab deruxtecan outperforms trastuzumab emtansine Presented ByDr Sara Hurvitz, University of California, CA, USA TrialPhase 3, DESTINY-Breast03 ConferenceSABCS 2021 31 January, 2022 18:02
Nivolumab plus ipilimumab serve promising dual checkpoint inhibition Presented ByDr Romualdo Barroso-Sousa , Hospital Sírio-Libanês, Brazil TrialPhase 2, NIMBUS ConferenceSABCS 2021 31 January, 2022 17:59
Entinostat plus exemestane improves progression-free survival in Chinese patients Presented ByProf. Binghe Xu, Chinese Academy of Medical Sciences, China ConferenceSABCS 2021 31 January, 2022 17:57
Efficacy of pyrotinib plus capecitabine confirmed in previously treated patients Presented ByProf. Binghe Xu, Chinese Academy of Medical Sciences, China TrialPhase 3, PHOEBE ConferenceSABCS 2021 31 January, 2022 17:54
Single-cell spatial analysis can predict response to neoadjuvant immunotherapy Presented ByDr Giampaolo Bianchini, Ospedale San Raffaele, Italy TrialPhase 3, NeoTRIPaPDL1 ConferenceSABCS 2021 31 January, 2022 17:48
Neoadjuvant pembrolizumab plus chemotherapy benefits event-free survival in TNBC Presented ByProf. Peter Schmid, Barts Cancer Institute, UK TrialPhase 3, KEYNOTE-522 ConferenceSABCS 2021 31 January, 2022 17:45
Early use of ctDNA testing can identify likelihood of relapse in TNBC Presented ByProf. Nicholas Turner, The Institute of Cancer Research, UK TrialPhase 2, c-TRAK-TN ConferenceSABCS 2021 31 January, 2022 17:42
Pembrolizumab plus chemotherapy benefits patients with combined positive score ≥10 Presented ByDr Javier Cortés, Vall d'Hebron Institute of Oncology, Spain TrialPhase 3, KEYNOTE-355 ConferenceSABCS 2021 31 January, 2022 17:40
Neratinib plus trastuzumab plus fulvestrant shows encouraging clinical activity Presented ByDr Komal Jhaveri, Memorial Sloan Kettering Cancer Center, NY, USA TrialPhase 2, SUMMIT ConferenceSABCS 2021 31 January, 2022 17:37
Addition of palbociclib to standard endocrine therapy does not improve outcome in adjuvant treatment Presented ByProf. Michael Gnant, Medical University of Vienna, Austria TrialPhase 3, PALLAS ConferenceSABCS 2021 31 January, 2022 17:31
The SERD elacestrant improves outcomes for patients unresponsive to endocrine therapy Presented ByDr Aditya Bardia, Massachusetts General Hospital, MA, USA TrialPhase 3, EMERALD ConferenceSABCS 2021 31 January, 2022 17:29
Consistent overall survival benefit of ribociclib in advanced breast cancer Presented ByProf. Lisa Carey & Dr Joyce O’Shaughnessy TrialPhase 3, MONALEESA ConferenceSABCS 2021 31 January, 2022 17:24
Premenopausal women benefit from adjuvant chemotherapy next to endocrine therapy Presented ByDr Kevin Kalinsky, Emory University Winship Cancer Institute, GA, USA TrialPhase 3, RxPONDER ConferenceSABCS 2021 31 January, 2022 17:19
Promising anti-tumour activity of the CDK7-inhibitor samuraciclib plus fulvestrant Presented ByProf. Charles Coombes, Imperial College London, UK ConferenceSABCS 2021 31 January, 2022 17:16
ctDNA is prognostic and predictive for response to ribociclib plus letrozole Presented ByDr Giampaolo Bianchini, San Raffaele Scientific Institute, Italy TrialPhase 3, BioItaLEE ConferenceSABCS 2021 31 January, 2022 17:13
Early switch to fulvestrant plus palbociclib beneficial for patients with ESR1 mutation Presented ByProf. François-Clément Bidard, Institut Curie, France TrialPhase 3, PADA-1 ConferenceSABCS 2021 31 January, 2022 17:09
Aromatase inhibitors outperform tamoxifen in premenopausal women Presented ByMs Rosie Bradley, University of Oxford, UK TrialPhase 3, ABCGS12; TEXT; SOFT; HOBOE ConferenceSABCS 2021 31 January, 2022 16:49
Concurrent taxane plus anthracycline most beneficial in reducing risk of breast cancer Presented ByDr Jeremy Braybrooke, University Hospitals Bristol NHS Foundation Trust, UK ConferenceSABCS 2021 31 January, 2022 16:44
Reduced risk of recurrence with ovarian suppression plus tamoxifen/exemestane Presented ByDr Meredith Regan, Dana-Farber Cancer Institute, USA TrialPhase 3, TEXT; SOFT ConferenceSABCS 2021 31 January, 2022 16:36
Metformin does not improve outcomes in patients with early-stage breast cancer Presented ByDr Pamela Goodwin, Lunenfeld-Tanenbaum Research Institute, Canada TrialPhase 3, CCTGMA.32 ConferenceSABCS 2021 31 January, 2022 16:32
Omitting sentinel lymph node biopsy improves arm symptoms Presented ByProf. Bernd Gerber, University of Rostock, Germany TrialINSEMA ConferenceSABCS 2021 31 January, 2022 16:29
Depression screening aids behavioral care referrals for breast cancer patients JournalJAMA 21 January, 2022 23:18
SABCS 2021 Highlights Podcast Presented ByDr Rachel Giles, Medicom ConferenceSABCS 2021 10 January, 2022 20:59
Better breast-cancer outcomes seen with integrative care JournalJournal of Oncology 3 January, 2022 16:12
GnRHa therapy protects the ovaries of young women with breast cancer having chemo JournalJAMA Oncology 3 January, 2022 15:53
NOS inhibitor plus taxane promising for resistant triple negative breast cancer JournalScience Translational Medicine 21 December, 2021 23:30
Pyrotinib plus chemo may improve outcomes in pretreated HER2-positive breast cancer ConferenceSan Antonio Breast Cancer Symposium 17 December, 2021 19:55
Tumor biology more important than race in predicting treatment response in breast cancer ConferenceSan Antonio Breast Cancer Symposium (SABCS) 15 December, 2021 16:18
Breast-cancer patients with estrogen-receptor mutation may benefit from early treatment change ConferenceSan Antonio Breast Cancer Symposium 13 December, 2021 17:03
Mammographic density linked to contralateral, but not ipsilateral, breast cancer risk in young survivors JournalJAMA Surgery 10 December, 2021 22:35
Matching breast-cancer treatments to high-value genomic alterations leads to better outcomes ConferenceSan Antonio Breast Cancer Symposium 10 December, 2021 16:04
Elacestrant could become new standard of care for some breast-cancer patients ConferenceSan Antonio Breast Cancer Symposium (SABCS) 9 December, 2021 16:06
Long-term safety of GnRHa affirmed in premenopausal women undergoing chemo for breast cancer JournalJournal of the National Cancer Institute 7 December, 2021 23:33
Fat cell alterations implicated in breast cancer metastases JournalScience Signaling 3 December, 2021 22:44
Structured exercise aids arm function after breast cancer surgery JournalThe BMJ 1 December, 2021 23:07
Four in 10 fractures in breast cancer patients are pathologic JournalJAMA Network Open 26 November, 2021 21:23
Trastuzumab deruxtecan triples PFS Presented ByDr Javier Cortés, International Breast Cancer Center Barcelona, Spain TrialPhase 3, DESTINY-Breast03 ConferenceESMO 2021 19 November, 2021 09:51
Novel conjugate meets primary endpoint Presented ByDr Cristina Saura, Vall d’Hebron Institute of Oncology, Spain TrialPhase 3, TULIP ConferenceESMO 2021 19 November, 2021 09:50
Longest survival benefit from first-line CDK4/6 inhibitor Presented ByProf. Gabriel Hortobagyi, University of Texas MD Anderson Cancer Center, USA TrialPhase 3, MONALEESA-2 ConferenceESMO 2021 19 November, 2021 09:50
Meta-analysis shows 6-months adjuvant trastuzumab is optimal Presented ByProf. Helena Earl, Addenbrooke's Hospital, UK ConferenceESMO 2021 19 November, 2021 09:50
BrighTNess data may change guidelines Presented ByProf. Sibylle Loibl, German Breast Group, Germany TrialPhase 3, BrighTNess ConferenceESMO 2021 19 November, 2021 09:49
Double-positive results for triple-negative metastatic breast cancer Presented ByProf. Hope Rugo, University of California, San Francisco, USA TrialPhase 3, KEYNOTE-355 ConferenceESMO 2021 19 November, 2021 09:48
Survival after neoadjuvant therapy with trastuzumab-lapatinib plus chemotherapy Presented ByProf. Valentina Guarneri, University of Padua, Italy ConferenceESMO 2021 19 November, 2021 09:48
Postmenopausal breast cancer: extended letrozole reduces recurrence Presented ByProf. Lucia Del Mastro, University of Genoa, Italy TrialPhase 3 ConferenceESMO 2021 19 November, 2021 09:47
Asian women also benefit from palbociclib plus letrozole Presented ByProf. Binghe Xu, Peking Union Medical College, Beijing, China TrialPhase 3, PALOMA-4 ConferenceESMO 2021 19 November, 2021 09:47
No PEARLs of survival with palbociclib plus endocrine therapy compared with capecitabine, but QoL better Presented ByProf. Miguel Martín Jiménez, Complutense University of Madrid, Spain TrialPhase 3, PEARL ConferenceESMO 2021 19 November, 2021 09:45
Women with breast cancer at increased risk for developing atrial fibrillation JournalEuropean Heart Journal 18 November, 2021 16:25
Patients with advanced breast cancer denied opportunities to join clinical trials ConferenceAdvanced Breast Cancer Sixth International Consensus Conference (ABC 6) 10 November, 2021 18:41
Acellular dermal matrix not tied to fewer reoperations after breast reconstruction JournalJAMA Network Open 4 November, 2021 22:09
Cancer patients treated with PARP inhibitors need monitoring for pancytopenia JournalJAMA Oncology 2 November, 2021 17:01
Eating nuts linked to lower risk of recurrence and death among breast-cancer survivors JournalInternational Journal of Cancer 25 October, 2021 19:15
Certain CDH1 variants tied to gastric cancer risk in hereditary lobular breast cancer JournalJAMA Surgery 22 October, 2021 23:59
Breast cancer patients often use cannabis and don’t tell physicians JournalCancer 12 October, 2021 22:38
Second-line trastuzumab deruxtecan for metastatic HER2-positive breast cancer: Interview with Javier Cortés ExpertProf. Javier Cortés , Vall d’Hebron Institute of Oncology, Barcelona, Spain TrialPhase 3, DESTINY-Breast03 ConferenceESMO 2021 12 October, 2021 10:31
Chronic stress hard on women with breast cancer ConferenceAACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved 8 October, 2021 15:54
ESMO 2021 Highlights Podcast Presented ByDr Rachel Giles, Medicom TrialDESTINY-Breast03, MONALEESA-2, KEYNOTE-716, CASPIAN, CheckMate-649, Impower010 ConferenceESMO 2021 4 October, 2021 09:27
Poor representation in breast-cancer clinical trials tied to real-world harms JournalJCO Oncology Practice ConferenceAmerican Society of Clinical Oncology Quality Care Symposium 29 September, 2021 18:24
Residual breast cancer burden after neoadjuvant chemo predicts survival JournalJAMA Oncology 23 September, 2021 22:59
Pembrolizumab a ‘game changer’ in some triple-negative breast cancers ConferenceESMO 2021 Congress 22 September, 2021 16:27
Young women who receive left-sided radiation for breast cancer at higher risk for heart disease JournalJACC: CardioOncology 21 September, 2021 22:32
Value of carboplatin added to neoadjuvant chemo in triple-negative breast cancer confirmed ConferenceESMO Congress 20 September, 2021 15:57
Radiologists outperform current AI systems for screening-mammography image analysis JournalThe BMJ 8 September, 2021 15:56
Increased breast cancer risk in women with schizophrenia taking certain antipsychotics JournalThe Lancet Psychiatry 3 September, 2021 19:21
In women with breast or ovarian cancer, pathogenic gene variants linked with increased survival JournalJournal of the National Cancer Institute 27 August, 2021 15:48
Clinical features, imaging may curb false-positive MRI breast findings JournalRadiology 19 August, 2021 23:13
Trastuzumab associated with cardiotoxicity in breast cancer Presented ByDr Ana Filipa Cardoso, Hospital Senhora da Oliveira-Guimarães, Portugal ConferenceHFA 2021 19 August, 2021 09:18
Breast cancer screening at 40 aids childhood cancer survivors treated without chest radiation JournalJournal of the National Cancer Institute 17 August, 2021 23:51
Excellent prognosis for breast cancer patients with ultra-low-risk gene signature Presented ByDr Josephine Lopes Cardozo, Netherlands Cancer Institute, the Netherlands TrialPhase 3, MINDACT ConferenceASCO 2021 12 August, 2021 23:45
Olaparib benefits early breast cancer patients with BRCA1/2 germline mutation Presented ByProf. Andrew Tutt , Institute of Cancer Research, UK TrialOlympiA ConferenceASCO 2021 12 August, 2021 22:47
Platinum-based adjuvant chemotherapy in TNBC is not superior or non-inferior to capecitabine Presented ByProf. Ingrid Mayer, Vanderbilt University School of Medicine, TN, USA TrialPhase 3, ECOG-ACRIN EA1131 ConferenceASCO 2021 12 August, 2021 21:50
Dalpiciclib benefits patients with HR-positive, HER2-negative advanced breast cancer Presented ByProf. Binghe Xu, Chinese Academy of Medical Sciences and Peking Union Medical College, China TrialPhase 3, DAWNA-1 ConferenceASCO 2021 12 August, 2021 20:52
Trastuzumab-deruxtecan showed clinical activity in patients with brain metastases Presented ByProf. Guy Jerusalem , CHU Liège, Belgium TrialPhase 2, DESTINY-Breast01 ConferenceASCO 2021 12 August, 2021 19:54
Novel compound shows promise in lab studies for resistant triple negative breast cancer JournalNature Communications, 10 August, 2021 18:59
Adding neoadjuvant anastrozole to trastuzumab deruxtecan in HER2-low breast cancer Presented ByDr Sarah Hurvitz , UCLA Jonsson Comprehensive Cancer Center TrialPhase 2, TALENT JournalPhysician's Weekly ConferenceASCO 2021 6 August, 2021 12:34
Adjuvant olaparib extends disease-free survival in BRCA carriers Presented ByDr. Judy Ellen Garber, Dana-Farber Cancer Institute, Harvard Medical School TrialOlympiA JournalPhysician's Weekly ConferenceASCO 2021 6 August, 2021 12:30
Preventing interstitial lung disease in patients on trastuzumab detruxtecan Presented ByDr Charles Powell, Mount Sinai-National Jewish Health Respiratory Institute TrialPhase 2, DESTINY-Breast01 JournalPhysician's Weekly ConferenceASCO 2021 6 August, 2021 12:10
T-DXd response on brain metastases in HER2+ breast cancer patients Presented ByProf. Guy Jerusalem, Liège University, Belgium TrialPhase 2, DESTINY-Breast01 JournalPhysician's Weekly ConferenceASCO 2021 6 August, 2021 11:48
T-DXd Combinations in HER2-positive Metastatic Breast Cancer Presented ByDr Fabrice André, Institut Gustave Roussy, Paris, France TrialPhase 2, DESTINY-Breast07 JournalPhysician's Weekly ConferenceASCO 2021 6 August, 2021 10:55
Statin use linked to improved outcome in tough-to-treat triple-negative breast cancer JournalCancer 4 August, 2021 17:10
HER2-low-positive breast cancer a distinct subgroup that behaves differently JournalLancet Oncology 30 July, 2021 16:41
Adding 3 extra years of hormone therapy shows no benefit in breast cancer study JournalThe New England Journal of Medicine 28 July, 2021 23:30
Remote monitoring of chemotherapy patients may help optimize care at home JournalThe BMJ 22 July, 2021 22:26
Real-world survival inferior to clinical trials for certain metastatic breast cancer treatments JournalJAMA Oncology 12 July, 2021 22:03
Tumor size, grade tied to long-term survival in selected breast cancer patients JournalJAMA Network Open 7 July, 2021 15:35
No benefit to adjuvant bisphosphonate beyond two years in early breast cancer JournalJAMA Oncology 29 June, 2021 22:15
No benefit to routine use of platinum agents after neoadjuvant chemo in triple-negative breast cancer JournalJournal of Clinical Oncology 17 June, 2021 19:05
Prevalence of breast-cancer-susceptibility genes similar in Black and white women JournalJAMA Oncology 14 June, 2021 17:43
Should the recurrence score for downstaging breast cancer be expanded? JournalJournal of the National Cancer Institute 11 June, 2021 21:46
New data support omission of anthracyclines in early-stage ERBB2-positive breast cancer JournalJAMA Oncology 10 June, 2021 23:13
Pro-inflammatory diet tied to increased risk of breast cancer JournalAmerican Society for Nutrition 10 June, 2021 16:06
Some patients with HER2-positive early breast cancer might not need chemo JournalThe Lancet Oncology 9 June, 2021 16:48
Olaparib cuts odds of invasive disease, death by 42% in some breast cancers JournalThe New England Journal of Medicine 3 June, 2021 23:31
Practicing-changing results for some early-stage BRCA-mutated breast cancers ConferenceASCO annual meeting 3 June, 2021 23:00
More breast-cancer patients using complementary medicine than their oncologists realize ConferenceAmerican Society of Clinical Oncology (ASCO) virtual annual meeting 26 May, 2021 20:04
CT scans for breast-cancer radiotherapy also show cardiovascular risk JournalJAMA Oncology 14 May, 2021 15:44
Interstitial lung disease a ‘manageable’ side effect of trastuzumab deruxtecan ConferenceESMO Breast Cancer 2021 Virtual Congress 14 May, 2021 15:38
Primary and recurrent breast tumors may have different HER2 status ConferenceESMO Breast Cancer 2021 Virtual Congress 11 May, 2021 16:25
Cryoablation may be a promising alternative to surgery for low-risk breast cancer ConferenceAmerican Society of Breast Surgeons (ASBrS) Annual Meeting 2021 4 May, 2021 15:56
Breast-cancer survivorship rarely easy, even with early-stage, low-risk disease ConferenceAmerican Society of Breast Surgeons annual meeting 3 May, 2021 20:47
Patients on hormonal therapies for cancer should be monitored for heart risk – AHA JournalCirculation: Genomic and Precision Medicine 26 April, 2021 19:18
SABCS 2020: Updated monarchE trial shows abemaciclib continues to benefit patients with high-risk, HR-positive, HER2-negative, early-stage breast cancer Presented ByDr Priya Rastogi, University of Pittsburgh, Pennsylvania TrialmonarchE, PALLAS, Penelope-B JournalPhysician's Weekly ConferenceSABCS 2020 15 April, 2021 16:14
SABCS 2020: Update from the DESTINY-Breast01 trial Presented ByDr Shanu Modi , Memorial Sloan Kettering Cancer Center TrialDESTINY-Breast01 JournalPhysician's Weekly ConferenceSABCS 2020 13 April, 2021 18:50
How to avoid chemotherapy overtreatment in breast cancer Presented ByDr Nadia Harbeck , University of Munich in Germany TrialADAPT JournalPhysician’s Weekly ConferenceSABCS 2020 13 April, 2021 17:22
SABCS 2020: Adding nivolumab to trastuzumab deruxtecan is well tolerated Presented ByErika Hamilton, Sarah Cannon Research Institute at Tennessee Oncology in Nashville, TN TrialDESTINY-Breast01 ConferenceSABCS 2020 13 April, 2021 17:11
Follow-up supports MammaPrint to guide chemo decisions, points to an ‘age effect’ JournalLancet Oncology 2 April, 2021 17:24
Four healthy eating patterns tied to lower mortality in women with breast cancer JournalJournal of the National Cancer Institute: Cancer Spectrum 17 March, 2021 21:42
Neoadjuvant chemo may top endocrine therapy in strongly HR-positive, ERBB2-negative breast cancer JournalJAMA Network Open 16 March, 2021 19:29
Risk-reducing salpingo-oophorectomy could curb breast cancer JournalJAMA Oncology 9 March, 2021 17:32
Many bilateral mastectomies done in women at low risk of contralateral cancer JournalJAMA Surgery 16 February, 2021 23:49
Should breast density at age 40 guide mammography screening strategy? JournalAnnals of Internal Medicine 9 February, 2021 00:27
Guidelines help individualize surveillance for older early-stage breast cancer survivors JournalJAMA Oncology 2 February, 2021 23:26
Aspirin tied to improved breast, bladder cancer survival in older adults JournalJAMA Network Open 26 January, 2021 21:33
Margetuximab outperforms trastuzumab in advanced HER2-positive breast cancer JournalJAMA Oncology 25 January, 2021 23:23
Androgen receptor has potent anti-tumor activity in ER+ breast cancer JournalNature Medicine 20 January, 2021 15:59
New tool helps predict chemotherapy toxicity in older women with early breast cancer JournalJournal of Clinical Oncology 14 January, 2021 22:00
Immune factors linked to poor survival in Black breast cancer patients, immunotherapy potentially helpful 12 January, 2021 23:11
Could statins protect the heart from breast-cancer chemotherapy? JournalJournal of the American Heart Association 6 January, 2021 16:36
MRI-based nomograms may predict lymph node metastasis, survival in early breast cancer JournalJAMA Network Open 16 December, 2020 23:48
Circulating-tumor-cell dynamics have prognostic value in metastatic breast cancer Conference2020 San Antonio Breast Cancer Symposium 15 December, 2020 20:34
Breast radiotherapy symptoms often under-recognized by providers Conference2020 San Antonio Breast Cancer Symposium 14 December, 2020 22:41
Mastectomy may raise risk of persistent use of opioids, sedative-hypnotics Conference2020 San Antonio Breast Cancer Symposium 11 December, 2020 17:18
Trade-offs to skipping radiotherapy after breast-conserving surgery in older women Conference2020 San Antonio Breast Cancer Symposium 10 December, 2020 16:37
Some older women with common breast cancer can skip adjuvant chemo Conference2020 San Antonio Breast Cancer Symposium 9 December, 2020 17:39
Fertility preservation tied to better reproductive outcomes after breast cancer JournalJAMA Oncology 1 December, 2020 22:35
Immediate breast reconstruction feasible following neoadjuvant chemo JournalJAMA Surgery 26 November, 2020 17:18
New assay platform enhances detection of circulating breast cancer cells JournalACS Sensors 25 November, 2020 21:12
Neoadjuvant treatment in patients with high-risk early breast cancer ConferenceESMO 2020 25 November, 2020 16:19
Prognostic value of tumour infiltrating lymphocytes in young TNBC patients ConferenceESMO 2020 25 November, 2020 16:16
Contradicting results for chemoimmunotherapy in metastatic TNBC ConferenceESMO 2020 25 November, 2020 16:01
Second-line sacituzumab govitecan improves survival in metastatic TNBC ConferenceESMO 2020 25 November, 2020 15:14
Breast density helps predict cancer-related lymphedema risk JournalJAMA Network Open 18 November, 2020 17:24
Risk of invasive breast cancer similar with family history of in situ or invasive disease JournalBMC Medicine 16 November, 2020 23:07
Image-guided biopsy may help some avoid breast-cancer surgery JournalJAMA Surgery 19 October, 2020 20:00
Gene signature predicts overall survival in women with breast cancer JournalJAMA Network Open 19 October, 2020 17:30
Textured implants linked to increased breast cancer recurrence risk JournalJAMA Surgery 13 October, 2020 23:27
Study helps gauge long-term risks for women with DCIS by treatment ConferenceEuropean Breast Cancer Conference 2020 7 October, 2020 21:04
Benign breast disease detected after baseline mammogram most apt to become cancer ConferenceEuropean Breast Cancer Conference 2020 6 October, 2020 18:33
Genetic test spots high-risk invasive lobular carcinoma ConferenceEuropean Breast Cancer Conference 2020 5 October, 2020 18:47
DCIS linked to higher breast cancer mortality, despite treatment JournalJAMA Network Open 24 September, 2020 23:35
Immunomedics drug Trodelvy extends survival in breast cancer patients ConferenceESMO 2020 21 September, 2020 16:40
Advanced breast cancer: locoregional therapy does not improve OS Presented ByProf. Seema A. Khan, Feinberg School of Medicine, USA TrialPhase 3, E2108 ConferenceASCO 2020 8 September, 2020 09:50
T-DM1 does not improve safety or efficacy in HER-2 positive early breast cancer; favorable iDFS reported Presented ByProf. N. Harbeck, University of Munich, Germany TrialPhase 3, KAITLIN ConferenceASCO 2020 8 September, 2020 09:40
Combination pembrolizumab/chemo improves PFS in metastatic TNBC Presented ByDr Javier Cortés & Catherine M. Kelly TrialKEYNOTE-355 ConferenceASCO 2020 8 September, 2020 09:32
Effect of veliparib with or without cisplatin in breast cancer: results of SWOG S1416 Presented ByDr Priyanka Sharma, University of Kansas Medical Center, USA TrialPhase 2, SWOG 1416 ConferenceASCO 2020 8 September, 2020 09:30
PHOEBE, a phase 3 trial comparing pyrotinib and lapatinib in HER2-positive metastatic breast cancer Presented ByDr Binghe Xu, Peking Union Medical College, China TrialPhase 3, PHOEBE ConferenceASCO 2020 8 September, 2020 09:10
BYLieve demonstrates efficacy of PIK3CA-directed treatment post CDK4/6-ihibition Presented ByProf. Hope S. Rugo, University of California San Francisco, CA, USA TrialPhase 2, BYLieve ConferenceASCO 2020 8 September, 2020 09:00
Strategies emerge for chemotherapy de-escalation in HER2-positive breast cancer Presented ByDr Javier Cortés, Vall d’Hebron Institute of Oncology, Spain TrialPhase 2, PHERGAIN ConferenceASCO 2020 8 September, 2020 08:50
MRI and 14G biopsies are not accurate enough in pCR detection TrialMICRA ConferenceSABCS 2019 13 February, 2020 23:54
No higher pathologic complete response with atezolizumab added to chemotherapy TrialIMpassion130 ConferenceSABCS 2019 13 February, 2020 23:54
Anastrozole yields long term effects in the prevention of breast cancer occurrence TrialIBIS-II ConferenceSABCS 2019 13 February, 2020 23:47
S-1 shows promising results in combination with endocrine therapy ConferenceSABCS 2019 13 February, 2020 23:40
Positive effects of adding pertuzumab to trastuzumab + chemotherapy in operable HER2 breast cancer TrialAPHINITY ConferenceSABCS 2019 13 February, 2020 23:13
High rates of ROR-low disease with chemotherapy-free regimen in HR+/HER2- patients TrialPhase 2, CORALLEEN ConferenceSABCS 2019 13 February, 2020 23:05
Breast cancer incidence decreased by oestrogen alone but increased by adding progestin ConferenceSABCS 2019 13 February, 2020 22:59
Neoadjuvant + adjuvant pembrolizumab improves pCR in triple-negative breast cancer with lymph node involvement TrialKEYNOTE-173, Phase 1b ; I-SPY 2, Phase 2 ; KEYNOTE-522, Phase 3 ConferenceSABCS 2019 13 February, 2020 22:56
HER2 antibody-drug conjugate T-DXd promising in T-DM1 pretreated patients TrialPhase 2, DESTINY-Breast01 ConferenceSABCS 2019 13 February, 2020 22:54
Partial breast irradiation could be as effective as whole breast irradiation TrialPhase 3, APBI IMRT ConferenceSABCS 2019 13 February, 2020 22:48
Better outcomes with oral paclitaxel than intravenous paclitaxel in metastatic breast cancer ConferenceSABCS 2019 13 February, 2020 22:42
Sensory peripheral neuropathy after taxane treatment is not uncommon ConferenceSABCS 2019 13 February, 2020 21:50
Subcutaneous pertuzumab + trastuzumab non-inferior to the IV combination TrialPhase 3, FeDeriCa ConferenceSABCS 2019 13 February, 2020 21:44
Palbociclib not statistically superior to capecitabine in PFS TrialPhase 3, PEARL ConferenceSABCS 2019 13 February, 2020 13:21
Circulating tumour DNA may help predict recurrence in patients with early triple-negative breast cancer TrialBRE12-158 ConferenceSABCS 2019 13 February, 2020 13:07
No added benefit for doxorubicin + docetaxel vs doxorubicin + cyclophosphamide ConferenceSABCS 2019 13 February, 2020 12:51
Clinical benefit over trastuzumab for margetuximab in HER2 breast cancer TrialPhase 3, SOPHIA ConferenceSABCS 2019 13 February, 2020 12:45
Residual cancer burden is a predictor for all-type breast cancer patients ConferenceSABCS 2019 13 February, 2020 12:11
Tamoxifen monotherapy may mean undertreatment for some luminal breast cancer patients TrialMINDACT, TAILORx ConferenceSABCS 2019 13 February, 2020 10:01
Triple negative breast cancer gets positive news: KEYNOTE-522 interim results Presented ByProf. Peter Schmid, Queen Mary University of London, UK TrialPhase 3, KEYNOTE-522 ConferenceESMO 2019 26 November, 2019 23:12
CDK4/6 inhibitors change landscape of breast cancer treatment: 2 studies Presented ByProf. Dennis Slamon, Prof. George Sledge, Prof. Nadia Harbeck TrialMonaleesa-3, Monarch 2 ConferenceESMO 2019 26 November, 2019 22:03
Veliparib-chemo combo prolongs survival without disease progression in some advanced breast cancer patients Presented ByVeronique Diéras, Centre Eugène Marquis, Rennes, France TrialPhase 3, BROCADE 3 ConferenceESMO 2019 26 November, 2019 14:04
Endocrine therapy plus ribociclib yields overall survival advantage in HR+/HER2-negative breast cancer Presented ByDr Sara A. Hurvitz, University of California, Los Angeles, Jonsson Comprehensive Cancer Centre TrialPhase 3, MONALEESA-7 ConferenceASCO 2019 15 July, 2019 15:00
Biomarker analysis predicts response to adjuvant trastuzumab, pertuzumab in HER2+ breast cancer Presented ByDr Ian E. Krop, Dana-Farber Cancer Institute, USA TrialPhase 3, APHINITY ConferenceASCO 2019 15 July, 2019 14:00
ImPassion130 brings breast cancer into the immunotherapy era TrialPhase 3, ImPassion130 ConferenceASCO 2019 15 July, 2019 11:27
Discordance of biomarkers in multifocal and lymph node positive breast cancer Presented ByDr Marie Sundquist, Kalmar County Hospital, Sweden ConferenceBCC 2019 21 May, 2019 23:51
Extrapolating data from clinical trials as we treat patients in real life Presented ByProf. Sharon Giordano, MD Anderson, Houston, USA TrialAPHINITY, KATHERINE, ExteNET ConferenceBCC 2019 21 May, 2019 23:44
Letter from the Editor EditorDr Stefan Rauh, Centre Hospitalier Emile Mayrisch, Esch, Luxembourg ConferenceBCC 2019 21 May, 2019 22:56
New Prognostic Biomarkers for Survival Breast Cancer Presented ByDr Jasmin Zeindler, University Hospital Basel, Switzerland ConferenceBCC 2019 21 May, 2019 22:53
What is the clinical benefit of treatment of patients with early breast cancer? Presented ByProf. Ann Partridge, Dana-Farber Cancer Institute, Boston, USA ConferenceBCC 2019 21 May, 2019 22:47
Adjuvant chemotherapy after neoadjuvant chemotherapy? Going beyond EMA/FDA TrialKATHERINE, CREATE-X ConferenceBCC 2019 21 May, 2019 16:29
Endocrine therapy in postmenopausal patients: a graded approach ConferenceBCC 2019 21 May, 2019 14:32
Selection of patients for neoadjuvant chemotherapy treatment based on oncotype recurrence score in luminal breast cancer Presented ByDr Ariadna Gasol Cudos, Hospital Universitari Arnau de Vilanova de Lleida, Spain ConferenceBCC 2019 21 May, 2019 09:55
Adjuvant and neoadjuvant therapy: principles and practical considerations Presented ByProf. Eric Winer, Dana-Farber Cancer Institute, Boston, USA TrialNSABP B-18, NSABP B-27, ACOSOG Z1071, NEO-ALTTO, APHINITY, I-SPY2 ConferenceBCC 2019 21 May, 2019 09:49